When it comes to reducing the cost of prescription medicines, where US President Donald Trump has increasingly failed, a new price transparency law in California appears to be succeeding.
The new law, called SB-17, requires drugmakers to give government, insurers and other payers advance notice of increases over a certain amount.
Apparently as a result of the law coming into effect, Switzerland’s Novartis (NOVN: VX) and Roche (ROG: SIX), as well as Gilead Sciences (Nasdaq: GILD) and Novo Nordisk (NOV: N), have either cancelled or reduced planned price increases for over 10 different products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze